DIVA Laboratories (4153) Fundamentals 2026 — P/E 20.4x, Revenue Analysis | SniperIQ
DIVA Laboratories (4153) is a TW-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of NT
1.20 on the TWO. This SniperIQ fundamentals page covers DIVA Laboratories's valuation (P/E 20.4x, P/B 2.0x), profitability (net margin 10.2%), revenue (NT$869M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is DIVA Laboratories's market cap?
DIVA Laboratories (4153) has a market capitalization of approximately NT
1.20 on the TWO. Market cap moves with the live share price.What is DIVA Laboratories's P/E ratio?
DIVA Laboratories's trailing twelve-month P/E ratio is 20.4x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is DIVA Laboratories?
DIVA Laboratories runs a net profit margin of 10.2%, a gross margin of 29.2%, and an operating margin of 11.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does DIVA Laboratories generate?
DIVA Laboratories reported revenue of NT$869M for fiscal year 2025, with net income of NT$91M and earnings per share (EPS) of 1.54. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does DIVA Laboratories pay a dividend?
DIVA Laboratories offers a trailing dividend yield of about 6.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is DIVA Laboratories financially healthy?
DIVA Laboratories carries a debt-to-equity ratio of 0.00x and a current ratio of 2.50x, with a market beta of 0.20. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is DIVA Laboratories a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For DIVA Laboratories (4153) the key facts are: market cap NT
Track DIVA Laboratories's full fundamentals live
Get DIVA Laboratories's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.